Progress of hearing loss in neurofibromatosis type 2: implications for future management

被引:18
|
作者
Kontorinis, Georgios [1 ,2 ]
Nichani, Jaya [1 ]
Freeman, Simon R. [1 ]
Rutherford, Scott A. [3 ]
Mills, Samantha [4 ]
King, Andrew T. [3 ]
Mawman, Deborah [1 ]
Huson, Sue [5 ]
O'Driscoll, Martin [1 ]
Gareth Evans, D. [5 ]
Lloyd, Simon K. W. [1 ,6 ,7 ]
机构
[1] Cent Manchester Univ Hosp, NHS Fdn Trust, Univ Dept Otolaryngol, Manchester M13 9PL, Lancs, England
[2] Southern Teaching Hosp, Inst Neurosci, Dept Otolaryngol, Glasgow, Lanark, Scotland
[3] Salford Royal NHS Fdn Trust, Dept Neurosurg, Manchester, Lancs, England
[4] Salford Royal NHS Fdn Trust, Dept Neuroradiol, Manchester, Lancs, England
[5] Cent Manchester Univ Hosp, NHS Fdn Trust, Dept Med Genet, Manchester M13 9PL, Lancs, England
[6] Univ Manchester, Sch Canc, Manchester M13 9PL, Lancs, England
[7] Univ Manchester, Enabling Serv, Manchester M13 9PL, Lancs, England
关键词
Conservative treatment; Deafness; Neurofibromatosis type 2; Tumour size; Vestibular schwannoma; Watch wait rescan protocol; VESTIBULAR SCHWANNOMAS; NATURAL-HISTORY; CONSERVATIVE MANAGEMENT; COCHLEAR IMPLANTATION; UNITED-KINGDOM; GROWTH; PRESERVATION; NF2;
D O I
10.1007/s00405-014-3317-7
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
The objective of this study was to describe changes in hearing over time in patients with neurofibromatosis type 2 (NF2) treated conservatively. A retrospective case review was conducted in a tertiary referral centre. Pure tone audiometry, speech discrimination scores, serviceable hearing (American Academy of Otolaryngology class A or B) and measurement of vestibular schwannoma (VS) size on magnetic resonance imaging were evaluated in 56 patients (89 ears) with NF2 with at least one conservatively managed VS. Over a mean follow-up period of 7 years (range 0.8-21 years) pure tone average thresholds increased gradually with a mean annual rate of 1.3 dB for the right ear (p = 0.0003) and 2 dB for the left ear (p = 0.0009). Speech discrimination scores dropped with an average annual rate of 1.3 and 0.34 % in the right and left ear, respectively. Patients maintained serviceable hearing for an average of 7.6 years (range 2.7-19.3 years). The average annual VS growth was 0.4 mm without any correlation with hearing loss. There was a correlation between patients' age and pure tone threshold increase (p < 0.05 for both ears). In this selected population of patients with NF2, hearing threshold increases were very slow. In NF2 patients with indolently behaving tumours, serviceable hearing can be maintained for a significant length of time, making conservative management an attractive option.
引用
收藏
页码:3143 / 3150
页数:8
相关论文
共 50 条
  • [21] Recent Therapeutic Progress and Future Perspectives for the Treatment of Hearing Loss
    Lye, Joey
    Delaney, Derek S.
    Leith, Fiona K.
    Sardesai, Varda S.
    McLenachan, Samuel
    Chen, Fred K.
    Atlas, Marcus D.
    Wong, Elaine Y. M.
    BIOMEDICINES, 2023, 11 (12)
  • [22] Hearing optimisation in neurofibromatosis type 2: A systematic review
    Lloyd, S. K. W.
    King, A. T.
    Rutherford, A.
    Hammerbeck-Ward, C. L.
    Freeman, S. R. M.
    Mawman, D. J.
    O'Driscoll, M.
    Evans, D. G.
    CLINICAL OTOLARYNGOLOGY, 2017, 42 (06) : 1329 - 1337
  • [23] Hearing Improvement after Bevacizumab for Neurofibromatosis Type 2
    Diao, Jian-Sheng
    Xia, Wen-Sen
    Guo, Shu-Zhong
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (18): : 1810 - 1810
  • [24] Hearing changes after diagnosis in neurofibromatosis Type 2
    Masuda, A
    Fisher, LM
    Oppenheimer, TL
    Iqbal, Z
    Slattery, WH
    OTOLOGY & NEUROTOLOGY, 2004, 25 (02) : 150 - 154
  • [25] Bevacizumab Impact on Hearing Loss Due to Neurofibromatosis Type 2 Associated Vestibular Schwannomas and Associated Biomarkers
    Blakeley, Jaishri
    Ye, Xiobu
    Duda, Gabriel
    Halpin, Christopher
    Bergner, Amanda
    Muzikansky, Alona
    Merker, Vanessa
    Gerstner, Elizabeth
    Fayad, Laura
    Ahlawat, Shivani
    Jacobs, Michael
    Jain, Rakesh
    Dombi, Eva
    Widemann, Brigitte
    Plotkin, Scott
    NEUROLOGY, 2016, 86
  • [26] Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation
    Bonne, Nicolas-Xavier
    Aboukais, Rabih
    Baroncini, Marc
    Hochart, Audrey
    Leblond, Pierre
    Broly, Franck
    Dubrulle, Frederique
    Lejeune, Jean-Paul
    Vincent, Christophe
    CHILDS NERVOUS SYSTEM, 2016, 32 (12) : 2403 - 2413
  • [27] Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation
    Nicolas -Xavier Bonne
    Rabih Aboukais
    Marc Baroncini
    Audrey Hochart
    Pierre Leblond
    Franck Broly
    Frédérique Dubrulle
    Jean-Paul Lejeune
    Christophe Vincent
    Child's Nervous System, 2016, 32 : 2403 - 2413
  • [28] Management strategies in neurofibromatosis type 2
    Moffat, DA
    Quaranta, N
    Baguley, DM
    Hardy, DG
    Chang, P
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2003, 260 (01) : 12 - 18
  • [29] Pathogenesis and management of type 2 neurofibromatosis
    McCabe, Martin G.
    Evans, Dafydd Gareth
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (03): : 281 - 292
  • [30] Management strategies in neurofibromatosis type 2
    David Moffat
    Nicola Quaranta
    David Baguley
    David Hardy
    Phillip Chang
    European Archives of Oto-Rhino-Laryngology, 2003, 260 : 12 - 18